Research evidence / Overview of studies for Alercina Plus
Research Evidence for Symptoms in Seasonal Allergic Rhinitis
This section will summarize the structure of Randomized Controlled Trials (RCTs) and Systematic Reviews that explored the combination in relation to short- to intermediate-term symptom patterns of hay fever. It will detail the specific outcomes and composite symptom scores that researchers measured in these studies.
Research exploring short-term symptom changes in seasonal allergic rhinitis (SAR), a condition characterized by fluctuating or episodic manifestations, includes Randomized Controlled Trials (RCTs). These studies were designed to evaluate the combination medicine against a placebo or against one of its active components taken alone. Researchers focused on a cluster of patient-reported outcomes describing perceived discomfort, including scores for symptoms like sneezing, runny nose, and, importantly, nasal congestion. Studies conducted during periods of increased symptom activity described patterns observed in the populations over defined observation periods (e.g., up to four weeks).
Despite the body of research, the long-term effects are not fully established. Follow-up durations were limited, as major trials focused on the acute and intermediate period (typically 4 weeks or less). There is limited information for long-term outcomes regarding the sustained symptomatic profile of the combination.
Research Evidence for Symptoms in Perennial Allergic Rhinitis
This block will describe the available research, including RCTs, which examined the medicine’s components in patients with year-round, persistent allergic symptoms. The summary will focus on the types of symptom tracking and the typical follow-up duration used in these chronic condition studies.
The research examined this medicine’s components in perennial allergic rhinitis (PAR), a condition involving periods of heightened symptoms throughout the year, and includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort, such as Total Nasal Symptom Scores (NTSS) and individual symptom ratings. Research describes the changes monitored when the combination was studied in adults with persistent rhinitis.
Because perennial rhinitis is a chronic condition, the research exploration over four weeks means that follow-up durations were limited relative to the condition’s nature. This provides limited insight into long-term changes, and there is limited information for long-term outcomes on the sustained relief of these year-round symptoms.
Research Evidence for Symptoms in Common Cold Symptom Clusters
This part will outline the Systematic Reviews and Meta-analyses that assessed the use of antihistamine-decongestant drug classes, including this combination, for reducing specific symptoms like nasal congestion during a common cold episode. It will clarify that the evidence often relates to patterns observed within the drug class across similar products.
Research examining temporary physiological imbalance during the common cold includes Systematic Reviews and Meta-analyses. The research was relevant in trials assessing short-term or episodic symptom patterns and focused on outcomes describing episodic or acute changes, such as global assessments of symptoms and specific scores for a stuffy or runny nose. Findings describe patterns observed in the studies regarding outcomes related to systemic or functional imbalance during the common cold.
However, the evidence is limited, as the research largely relies on evidence from the drug class rather than this single specific product. Furthermore, evidence quality varies across studies, and the certainty remains low for the magnitude of change in certain individual symptoms, such as a runny nose.
Duration of Studies and Long-Term Follow-up
The majority of pivotal studies for the combination medicine applied in research exploring short-term symptom changes. These trials typically observed participants for an intermediate period, lasting up to four weeks (28 days).
Currently, long-term effects are not fully established because follow-up durations were limited. Research provides context but not individual predictions regarding symptom control beyond this four-week mark.
Research in Specific Populations
The evidence base for the combination medicine was evaluated in populations that primarily included Adults and Adolescents (age 12 and older). These results apply only to the populations studied. Research described the symptom patterns observed in specific patient groups who had concomitant mild-to-moderate asthma alongside their allergic rhinitis. Data for younger children remain insufficient, as do data for other specific groups, such as pregnant individuals or those with other chronic conditions.
Research Gaps and Limitations
Research highlights what is known—and what is still uncertain—about this combination. A key limitation is that follow-up durations were limited across the major trials, meaning that long-term effects are not fully established.
For the common cold, evidence quality varies across studies, and the research often relies on evidence from the drug class rather than this single specific product. Finally, comparative evidence is lacking in some scenarios, and research does not determine whether an individual will respond similarly to the group patterns observed in the studies.
Key Studies & References
- ZYRTEC-D (cetirizine hydrochloride and pseudoephedrine hydrochloride extended release) tablet - DailyMed
